TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive OSI “Front Line Office” In Probes Of Scientific Misconduct, Kimes Tells NCAB October 13, 1989
TCL Archive In Brief: DCPC Still Looking For Yates’ Replacement New jersey Commission Offers New Fellowships December 4, 1987
